Eloxx Pharmaceuticals annual revenue
2010
2012
2013
2014
2022
2023
2024
2025
Eloxx Pharmaceuticals Revenue Growth & History (ELOX)
Eloxx Pharmaceuticals reported $0 in revenue for fiscal 2025, a decrease of 100.00% from the previous fiscal year.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$6.4M | −100.00% |
| 2024 | 2024-12-31 | $6.4M | $6.4M | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2014 | 2014-06-30 | $182,229 | $174,410 | +2230.59% |
| 2013 | 2013-06-30 | $7,819 | −$192,181 | −96.09% |
| 2012 | 2012-06-30 | $200,000 | — | — |
| 2010 | 2010-06-30 | $140,000 | — | — |
Eloxx Pharmaceuticals quarterly revenue
Q2.12
Q3.12
Q2.13
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q2 2013 | 2012-12-31 | $0 | −$200,000 | −100.00% |
| Q3 2012 | 2012-03-31 | $0 | — | — |
| Q2 2012 | 2011-12-31 | $200,000 | — | — |
Eloxx Pharmaceuticals revenue growth trends
Eloxx Pharmaceuticals's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
